NEWS!!
Biomark Diagnostics closes $572,569 private placement
2017-05-08 11:44 ET - News Release
Mr. Rashid Bux reports
BIOMARK CLOSES PREVIOUS ANNOUNCED PRIVATE PLACEMENT OFFERING
Biomark Diagnostics Inc. has closed the private placement announced on June 24, 2016.
Biomark closed its first tranche of private placement on March 15, 2016, for proceeds of $408,954 followed by a second tranche of a non-brokered private placement for gross proceeds of $163,615, wherein Biomark issued a total of 3,817,127 units at a price of 15 cents per unit.
Each unit consists of one common share of Biomark and one-half of one share purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share of Biomark at 30 cents per share for a period of one year from the closing date of the private placement, subject to an acceleration clause. Finders' fees were payable on the private placement.
The proceeds of the private placement was used for the continuation of the company's phase 3 clinical trials and general working capital. The securities issued under the private placement will be subject to a hold period of four months and one day.
About Biomark Diagnostics Inc.
Biomark Diagnostics is developing proprietary, non-invasive and accurate cancer diagnostic solutions, which can help detect, monitor and assess treatment for cancer early and cost-effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.
We seek Safe Harbor.
© 2017 Canjex Publishing Ltd. All rights reserved.